Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes

Journal of Diabetes Investigation

Volumn 1, Issue 6, 2010, Pages 283-285

  Shibasaki, Saeko ^a   Imagawa, Akihisa ^a,b   Terasaki, Jungo ^a   Hanafusa, Toshiaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fulminant type 1 diabetes; M value; Serum C peptide

Indexed keywords

BIPHASIC INSULIN; C PEPTIDE; GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME IMMUNOASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS;

EID: 79953745843     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00059.x     Document Type: Article

References (8)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31: S55-S60.
2. Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000; 342: 301-307.
3. Imagawa A, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 2003; 26: 2345-2352.
4. Horie M, Ueda K, Shibasaki S, et al. The assessment of low-dose serum C-peptide secretion clarified by chemilumi-nescent enzyme immunoassay and its clinical effectiveness. J Japan Diab Soc 2008; 51: 639-644 (in Japanese).
5. Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 2007; 3: 36-45.
6. Murase Y, Imagawa A, Hanafusa T, et al. Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy - a nationwide 5-year-study in Japan. Diabetologia 2007; 50: 531-537.
7. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 1988; 37: 81-88.
8. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.